Drug application
DARIFENACIN HYDROBROMIDE (DARIFENACIN HYDROBROMIDE)
Drugs@FDA ANDA 207664 · CIPLA
Key facts
| Drug name | DARIFENACIN HYDROBROMIDE |
|---|---|
| Active ingredients | DARIFENACIN HYDROBROMIDE |
| Application type | ANDA |
| Application number | 207664 |
| Company | CIPLA |
| Dosage forms | TABLET, EXTENDED RELEASE, ORAL |
| Strength | EQ 7.5MG BASE |
| Marketing status | Prescription |
| TE codes | AB |
| Reference listed drug | No |
| Latest submission status date | Sep 1, 2016 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- None Label versions
- 1–9 Products
- 1–9 Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.